[Features of the clinical picture of affective disorders in women during the menopausal transition and early postmenopause].

Objective: To determine the clinical and psychopathological features of affective disorders in women in the perimenopausal and early postmenopausal periods.

Material And Methods: The study included 90 female patients receiving inpatient psychiatric care for affective disorders, among them 41 patients were perimenopausal (group 1) and 49 were early postmenopausal (group 2). Clinical and psychopathological, psychometric (the Hospital Anxiety and Depression Scale - HADS, the Hamilton Depression and Anxiety Scales - HAM-D and HAM-A, the Hypomania Checklist-32 - HCL-32, the Bipolarity Index (BI), the Insomnia Severity Index - ISI, the Pittsburgh Sleep Quality Index - PSQI) and statistical methods were used.

Processed pseudogene insertion in GLB1 causes Morquio B disease by altering intronic splicing regulatory landscape.

Morquio B disease (MBD) is an ultra-rare lysosomal storage disease, which represents the relatively mild form of GLB1-associated disorders. In this article, we present the unique case of "pure" MBD associated with an insertion of the mobile genetic element from the class of retrotransposons. Using whole-genome sequencing (WGS), we identified an integration of the processed pseudogene NPM1 deep in the intron 5 of GLB1.

A new species of the late Miocene charadriiform bird (Aves: Charadriiformes), with a summary of all Paleogene and Miocene Charadrii remains.

A new species, Cherevychnavis umanskae sp. nov., (Aves: Charadriiformes) from the late Miocene of Ukraine is described, and all known fossils of the suborder Charadrii from the Paleogene and Miocene are summarized.

[A role of progesterone and its metabolites in regulation functions of the brain].

The review presents literature data reflecting the nature and mechanism of the effect of progesterone and its metabolites on human and animal brain structures. Particular attention is paid to neuroprotective, anticonvulsant, anti-anxiety and sedative properties of this hormone, which determines the prospect of its use for the prevention and treatment of human neurodegenerative diseases, epilepsy, sleep disorders, and anxiety-depressive spectrum disorders, including premenstrual and climacteric syndromes.